---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-001216"
form_type: "8-K"
ticker: "SBFM"
cik: "0001402328"
company_name: "Sunshine Biopharma Inc."
filed_at: "2026-02-20T23:59:59+00:00"
generated_at: "2026-05-16T01:25:44.829953+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Majority shareholder approves reverse stock split up to 1-for-10 for Sunshine Biopharma

## Summary
- Dr. Steve N. Slilaty, holding ~96% voting power, approved by written consent a reverse split of common stock up to 1-for-10.
- Board has discretion on whether to effect the reverse split and the exact ratio (whole number up to 1-for-10).
- Shareholder consent will be effective 20 days after mailing definitive information statement to stockholders.
- Dr. Slilaty is CEO and controls approximately 96% of total voting power.

## SEC filing metadata
- accession: 0001683168-26-001216
- form_type: 8-K
- ticker: SBFM
- cik: 0001402328
- company_name: Sunshine Biopharma Inc.
- filed_at: 2026-02-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1402328/000168316826001216/0001683168-26-001216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1402328/000168316826001216/sunshine_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-001216
- JSON: https://secwatch.observer/filing/0001683168-26-001216.json
- Plain text: https://secwatch.observer/filing/0001683168-26-001216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.